What is the 13F Pro Quality Score for QCLS?

13F Pro ranks Q/C TECHNOLOGIES, INC. (QCLS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View QCLS's current score at https://13fpro.ai/research/QCLS (free sign-up required for the full ranking).

Which hedge funds own the most QCLS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of QCLS include Quinn Opportunity Partners, JANE STREET GROUP,, UBS Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/QCLS as soon as new 13F filings post.

Where does 13F Pro source QCLS data?

All Q/C TECHNOLOGIES, INC. fundamentals and ownership data come directly from SEC EDGAR. Q/C TECHNOLOGIES, INC. files with the SEC under CIK 1321834. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is QCLS in?

Q/C TECHNOLOGIES, INC. (QCLS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is QCLS research updated on 13F Pro?

QCLS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Q/C TECHNOLOGIES, INC.(QCLS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1321834 QCLS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

QCLS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Q/C TECHNOLOGIES, INC. (QCLS), a Healthcare sector company. QCLS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), Q/C TECHNOLOGIES, INC. reports net income of $-1.2M, free cash flow of $-3.3M. Top institutional holders of QCLS by reported 13-F value include Quinn Opportunity Partners, JANE STREET GROUP,, UBS Group AG, based on the most recent SEC filings. QCLS trades on the Nasdaq exchange and files with the SEC under CIK 1321834. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QCLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Q/C TECHNOLOGIES, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.2M

Free Cash Flow

Q1 2026

$-3.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY18 $1.7MFY19 $1.6MFY22 —FY25 —

Net Income

+23.5% YoY

$-11.6MFY 2025

FY18 $-10.8MFY19 $-3.9MFY22 $-15.2MFY25 $-11.6M

Operating Income

+35.6% YoY

$-9.8MFY 2025

FY18 $-10.1MFY19 $-3.5MFY22 $-15.3MFY25 $-9.8M

EPS (Diluted)

+26.2% YoY

$-8.66FY 2025

FY18 —FY19 —FY22 $-11.74FY25 $-8.66

Total Assets

+134.7% YoY

$41.2MFY 2025

FY18 $7.8MFY19 $10.9MFY22 $17.5MFY25 $41.2M

Op. Cash Flow

+26.1% YoY

$-9.1MFY 2025

FY18 $-8.5MFY19 $-3.1MFY22 $-12.3MFY25 $-9.1M

Metric	FY 2025	FY 2022	FY 2019	FY 2018	FY 2017	FY 2015
Revenue	—	—	$1.6M -5.3%	$1.7M -50.4%	$3.4M +58.6%	$2.1M
Net Income	$-11.6M +23.5%	$-15.2M -290.9%	$-3.9M +64.2%	$-10.8M -47.3%	$-7.4M +20.9%	$-9.3M
Operating Income	$-9.8M +35.6%	$-15.3M -340.2%	$-3.5M +65.5%	$-10.1M -52.1%	$-6.6M +31.7%	$-9.7M
EPS (Diluted)	$-8.66 +26.2%	$-11.74	—	—	—	—
Total Assets	$41.2M +134.7%	$17.5M +61.1%	$10.9M +39.4%	$7.8M -16.4%	$9.3M +12.9%	$8.3M
Operating Cash Flow	$-9.1M +26.1%	$-12.3M -299.1%	$-3.1M +63.8%	$-8.5M -67.4%	$-5.1M	—

AI Insight: QCLS Financial Trends

Q/C Technologies remains unprofitable with deteriorating Q4 2025 losses and volatile equity base, despite marginal improvements in Q1 2026.

• Net losses widened to $6M in Q4 2025 from $2M–$3M range in prior quarters, then improved to $1M loss in Q1 2026.

• Operating cash outflow averaged $2M–$3M per quarter; Q3 2025 showed temporary improvement to $1M outflow but deteriorated again.

• Equity capital fluctuated sharply: fell from $17M (Q3 2024) to $5M (Q2 2025), then rebounded to $22M (Q4 2025) and settled at $21M (Q1 2026).

⚠ Q4 2025 marked worst quarter on record: $6M net loss and $4M operating loss — triple prior run rates.

⚠ Revenue data absent across all periods; inability to assess topline trajectory or burn-rate sustainability.

⚠ Equity swings (9pp range Q3 2024–Q2 2025) suggest capital raises/dilution or material write-downs — requires disclosure clarity.

AI Insight: QCLS Ratio Trends

Q/C Technologies remains deeply unprofitable, but ROE and ROA showed marked sequential improvement in Q1 2026.

• ROE improved to -24.0% in Q1 2026 from -108.4% in Q4 2025; ROA similarly recovered to -13.0% from -57.3%.

• ROIC deteriorated to -35.8% in Q1 2026 versus -50.0% in Q3 2025, though less negative than Q4 2025's -68.3%.

• TTM profitability metrics remain deeply negative: ROE -56.7%, ROA -30.7%, ROIC -44.5%.

⚠ Sustainability of Q1 2026 improvement uncertain given prior quarter volatility and continued negative returns.

⚠ No operating or net margin data available; inability to assess expense control or gross profitability trends.

Get alerted when QCLS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Q/C TECHNOLOGIES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of QCLS

Quinn Opportunity Partners LLC
$729.3K211,390 sh
JANE STREET GROUP, LLC
$435.3K126,188 sh
UBS Group AG
$269.1K77,989 sh
ADAR1 Capital Management, LLC
$172.5K50,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$163.5K47,390 sh
VANGUARD CAPITAL MANAGEMENT LLC
$129.4K37,511 sh
DIMENSIONAL FUND ADVISORS LP
$65.8K19,058 sh
VANGUARD FIDUCIARY TRUST CO
$53.7K15,555 sh
STATE STREET CORP
$44.5K12,905 sh
Sunbelt Securities, Inc.
$6.0K1,750 sh

Fund	Value	Shares
Quinn Opportunity Partners LLC	$729.3K	211,390
JANE STREET GROUP, LLC	$435.3K	126,188
UBS Group AG	$269.1K	77,989
ADAR1 Capital Management, LLC	$172.5K	50,000
GEODE CAPITAL MANAGEMENT, LLC	$163.5K	47,390
VANGUARD CAPITAL MANAGEMENT LLC	$129.4K	37,511
DIMENSIONAL FUND ADVISORS LP	$65.8K	19,058
VANGUARD FIDUCIARY TRUST CO	$53.7K	15,555
STATE STREET CORP	$44.5K	12,905
Sunbelt Securities, Inc.	$6.0K	1,750

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put QCLS on your watchlist

Track score changes the day Q/C TECHNOLOGIES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is QCLS a good stock to buy?

13F Pro's AI-powered analysis of Q/C TECHNOLOGIES, INC. (QCLS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QCLS are available on the QCLS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own QCLS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QCLS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Q/C TECHNOLOGIES, INC.'s investment landscape.